Elevation Oncology Inc reports results for the quarter ended in September - Earnings Summary

Elevation Oncology

02/11/2023 13:03

* Elevation Oncology Inc  ELEV.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of $-1.67.  The mean expectation of four analysts
for the quarter was for a loss of 32 cents per share. Wall
Street expected results to range from -39 cents to -25 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Elevation Oncology Inc's reported EPS for the quarter was
a loss
of 25 cents​.
    * The company reported a quarterly loss of $10.63 million.
    * Elevation Oncology Inc shares had fallen by 33.6% this
quarter and lost 53.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Elevation
Oncology Inc is $5.00 

This summary was machine generated from LSEG data November 2 at
01:03 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.32          -0.25          Beat
 Jun. 30 2023      -0.32          -0.37          Missed
 Mar. 31 2023      -0.59          -0.72          Missed
 Dec. 31 2022      -0.78          -0.82          Missed